KLK3 and prostate cancer: The clinical outcomes of each treatment were evaluated by the percentage of change in prostate-specific antigen (PSA) from baseline at 12 weeks (or earlier for those who discontinued treatment) and PSA progression-free survival (PSA-PFS) according to Prostate Cancer Working Group 2 Criteria16.